Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-19-039650
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-13 18:08:43
Reporting Period:
2019-08-09
Accepted Time:
2019-08-13 18:08:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1409212 P. Kathleen Bloch C/o Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-09 1,500 $5.52 13,500 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 288,895 Direct
Footnotes
  1. Includes (i) 9,000 shares held by the reporting person's husband in a 401(k) account and (ii) 4,500 shares held by the reporting person's husband in an IRA account, including the 1,500 shares reported on this Form 4. The reporting person may be deemed the beneficial owner of such shares.
  2. Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon a "Change In Control" of the issuer, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016, and (d) 110,000 RSUs granted on April 8, 2015; (ii) the following RSUs subject to vesting in three equal annual installments with the first of such vesting on the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 28,667 RSUs granted on July 22, 2019 and unvested as of the date hereof, (b) 11,567 RSUs granted on February 28, 2018 and unvested as of the date hereof, and (c) 2,714 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 64,447 shares of common stock owned by the reporting person.